Biobanking Market
Biobanking Market by Product (Equipment, Consumables), Software, Services, Workflow (Collection, Storage, Transport), Operation, Sample type (Blood, Stem Cells, Nucleic Acid), Application, Ownership, Region, End User, Competition - Global Forecast to 2031
BIOBANKING MARKET SIZE, SHARE & GROWTH SNAPSHOT
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
The global biobanking market is projected to grow from USD 8.09 billion in 2026 to USD 12.38 billion by 2031, at a CAGR of 8.9% during the forecast period. The market was valued at USD 7.65 billion in 2025. It includes technologies, products, and services for collecting, processing, storing, preserving, managing, and distributing biological samples and related data. The market features biobanking equipment, consumables, storage solutions, sample and information management systems, and various services. It covers diverse biological materials such as blood, tissues, organs, fluids, stem cells, nucleic acids, and human waste. These solutions support pharmaceutical, biotech, academic, research, hospital, diagnostic, CRO, and biobank sectors, facilitating applications like drug discovery, biomarker and disease research, precision medicine, clinical studies, genomics, and regenerative medicine.
KEY TAKEAWAYS
-
MARKET SNAPSHOT:
Base Year Market Size (2025): USD 7.65 Billion
Current Market Size (2026): USD 8.09 Billion
Forecast Market Size (2031): USD 12.38 Billion
CAGR (2026–2031): 8.9% -
SEGMENT LEADERSHIP:
Regional Leader: North America accounted for the largest market share of ~43.3% in 2025.
Offering Leader: Products segment accounted for the largest market share of ~65.2% in 2025.
Equipment Leader: Automated equipment is projected to be the fastest-growing segment, at a CAGR of 8.9% during the forecast period.
Workflow Leader: Sample collection & storage accounted for the largest share in 2025.
Biobank Leader: Biobanks dominated in 2025, with 53.3% of the market. -
MARKET OUTLOOK & COMPETITIVE LANDSCAPE:
Thermo Fisher Scientific Inc, PHC Holdings Corporation, and BD & Co were identified as some of the star players in the global biobanking market, given their strong market share and product and service footprint.
Askion, Cureline, and Baybiosciences have distinguished themselves among startups and SMEs by securing strong footholds in specialized niche areas, underscoring their potential as emerging market leaders.
The global biobanking market is expanding steadily, driven by the growing demand for high-quality biological samples, increasing investments in precision medicine and biopharmaceutical research, and rising adoption of advanced biobanking technologies across drug discovery, biomarker research, clinical research, genomics, and translational research.
TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' CUSTOMERS
Customer-side business trends in the biobanking market are driven by rising demand for high-quality biospecimens, precision medicine, and advanced biomedical research. Key trends include the growing use of diverse, well-characterized biospecimens; the expansion of population-based and disease-specific biobanks; the adoption of automated sample management and digital biobanking platforms; and increased outsourcing to biobanking service providers. Standardized sample collection, improved cryogenic storage, data integration, supply-chain traceability, and regulatory compliance are also shaping biobank development, procurement, sample management, and purchasing decisions.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
MARKET DYNAMICS
Level
-
Increasing adoption of precision medicine and biomarker-driven drug development
-
Growth of cell & gene therapy and other complex biologics manufacturing
Level
-
High capital investment required for biobank infrastructure
-
Stringent regulatory and ethical requirements for human biospecimen handling
Level
-
Growing focus on decentralized trials, remote collection and distributed patient access
-
Outsourcing of activities by SME biopharma companies to third party specialists
Level
-
Cybersecurity, interoperability and AI governance
-
Challenges associated with maintaining long-term sample quality and integrity
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Driver: Increasing adoption of precision medicine and biomarker-driven drug development
Increasing adoption of precision medicine and biomarker-driven drug development is driving demand for well-characterized samples supporting discovery and validation.
Restraint: High capital investment required for biobank infrastructure
High capital investment required for biobank infrastructure limits adoption among smaller institutions due to costly storage systems, equipment, and maintenance.
Opportunity: Growing focus on decentralized trials, remote collection and distributed patient access
Growing focus on decentralized trials, remote collection, and distributed patient access creates demand for decentralized biobanking networks and sample logistics.
Challenge: Cybersecurity, interoperability and AI governance
Cybersecurity, interoperability, and AI governance pose challenges in protecting sensitive sample data, integrating systems, and ensuring transparent, compliant AI use.
BIOBANKING MARKET: COMMERCIAL USE CASES ACROSS INDUSTRIES
| COMPANY | USE CASE DESCRIPTION | BENEFITS |
|---|---|---|
 |
Provides biobanking solutions including sample collection and preparation equipment, cryogenic tubes and containers, ultra-low-temperature freezers, automated sample handling, cold-chain logistics, and data management solutions for research and clinical biobanks | Enables secure preservation and traceability of biological samples while supporting standardized collection, processing, storage, transport, and inventory management across biobanking workflows |
 |
Provides automated and outsourced biobanking solutions covering biological sample storage, biorepository services, sample tracking, cold-chain logistics, automated retrieval, and Limfinity® biobanking LIMS for lifecycle management of research and clinical samples | Improves sample integrity, traceability, retrieval efficiency, and inventory visibility while enabling compliant, scalable management of biological samples across multiple storage locations |
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET ECOSYSTEM
The global biobanking market functions as a highly interconnected ecosystem where pharmaceutical and biotech firms, academic and research institutions, hospitals, diagnostic labs, and biobanks work together to gather, process, preserve, store, and manage biological samples and related data. Technology providers supply advanced sample collection systems, automated storage and retrieval platforms, cryogenic devices, lab instruments, consumables, and biobanking information management tools. Contract research organizations (CROs), biorepository service providers, and specialized logistics firms support sample collection, processing, storage, inventory management, transportation, and distribution throughout research and clinical development processes. Regulatory agencies and healthcare systems in regions like North America and Europe set evolving standards for sample quality, traceability, data privacy, ethical use, and biospecimen management—fostering standardization, automation, compliance, and adoption of biobanking solutions in fields such as precision medicine, drug discovery, biomarker research, clinical research, genomics, and translational science.
Logos and trademarks shown above are the property of their respective owners. Their use here is for informational and illustrative purposes only.
MARKET SEGMENTS
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
Global Biobanking Market, by Offering
In 2025, products accounted for the largest share, supported by widespread adoption of biobanking equipment, consumables, storage systems, sample collection products, and preservation solutions.
Global Biobanking Market, by Equipment
In 2025, manual equipment accounted for the largest share, driven by its widespread use in sample collection, processing, handling, and storage across biobanks and research laboratories.
Global Biobanking Market, by Workflow
In 2025, sample collection & storage accounted for the largest share, supported by the growing need for standardized collection, preservation, and long-term storage of biological specimens.
Global Biobanking Market, by Sample Type
In 2025, blood products accounted for the largest share, driven by their extensive use in disease research, biomarker discovery, diagnostics, and clinical research.
Global Biobanking Market, by Product End User
In 2025, biobanks accounted for the largest share, reflecting their extensive use of biobanking products for sample collection, processing, preservation, storage, and inventory management.
Global Biobanking Market, by Service Type
In 2025, physical biobanking services accounted for the largest share, driven by increasing outsourcing of sample collection, processing, storage, retrieval, and distribution activities.
Global Biobanking Market, by Ownership
In 2025, private & commercial biobanks accounted for the largest share, supported by increasing investments in biospecimen repositories and growing demand from pharmaceutical and biotechnology companies.
Global Biobanking Market, by Service End User
In 2025, pharmaceutical & biotechnology companies accounted for the largest share, driven by increasing demand for high-quality biospecimens supporting drug discovery, biomarker research, and clinical development.
Global Biobanking Market, by Application
In 2025, research applications accounted for the largest share, supported by increasing use of biological samples in disease research, drug discovery, biomarker identification, and translational research.
REGION
Asia Pacific to be fastest-growing region in market during forecast period
During the forecast period, Asia Pacific is expected to experience rapid growth in the biobanking market, driven by rising investments in precision medicine, genomics, and biomedical research, as well as the growing adoption of advanced technologies for sample collection, processing, preservation, and storage. The expansion of pharmaceutical and biotechnology research, biobanking infrastructure, CRO services, and clinical research activities further supports regional market growth.
BIOBANKING MARKET: COMPANY EVALUATION MATRIX
In the global biobanking market, Thermo Fisher Scientific is the leading player, supported by its broad portfolio of sample collection, storage, processing, monitoring, and laboratory solutions. Its strong presence across research and biopharmaceutical organizations, along with a focus on automation and sample integrity, reinforces its market leadership. Agilent Technologies is an emerging player, driven by its SLIMS biobanking software, which supports sample tracking, inventory management, workflow automation, and data management. Its growing focus on digital biobank management and integrated workflows positions it well to benefit from increasing biobank automation.
Source: Secondary Research, Interviews with Experts, MarketsandMarkets Analysis
KEY MARKET PLAYERS
- Thermo Fisher Scientific (US)
- PHC Holdings (Japan)
- BD & Co. (US)
- QIAGEN (Germany)
- Merck (Germany)
- LabCorp (US)
- Eurofins Scientific (Luxembourg)
- Agilent Technologies (US)
MARKET SCOPE
| REPORT METRIC | DETAILS |
|---|---|
| Market Size in 2025 (Value) | USD 7.65 Billion |
| Market Size in 2026 (Value) | USD 8.09 Billion |
| Market Forecast in 2031 (Value) | USD12.38 Billion |
| Growth Rate | CAGR of 8.9% from 2026 to 2031 |
| Years Considered | 2024–2031 |
| Base Year | 2025 |
| Forecast Period | 2026–2031 |
| Units Considered | Value (USD Million/Billion) |
| Report Coverage | Revenue Forecast, Company Ranking, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered |
|
| Regions Covered | North America, Europe, Asia Pacific, Latin America, Middle East, Africa |
WHAT IS IN IT FOR YOU: BIOBANKING MARKET REPORT CONTENT GUIDE
DELIVERED CUSTOMIZATIONS
We have successfully delivered the following deep-dive customizations:
| CLIENT REQUEST | CUSTOMIZATION DELIVERED | VALUE ADDS |
|---|---|---|
| Evaluate the competitive positioning of key players in the biobanking market | Benchmarked leading companies across biobanking equipment, consumables, sample storage, automation, monitoring systems, informatics, and biobanking services based on technology capabilities, workflow coverage, product and service offerings, geographic reach, and end-user focus | Identifies competitive gaps, technology differentiation opportunities, strategic partnerships, and market positioning strategies |
| Assess high-growth biobanking technologies and application opportunities | Evaluated growth potential across automated biobanking, cryogenic storage, sample management and tracking, digital biobank platforms, biospecimen processing, and integrated biobanking workflows | Supports investment prioritization, technology development, portfolio expansion, automation strategies, and service diversification |
RECENT DEVELOPMENTS
- January 2026 : PHC Corporation launched ECO 703VXH in North America for biorepositories, biopharmaceutical companies, and academic institutions. The freezer combines dual independent refrigeration, natural refrigerants, to support secure long-term storage of vaccines, cell lines, and therapeutic samples.
- March 2025 : Cryoport launched MVE Biological Solutions' (MVE) High-Efficiency 800 C, an addition to its next-generation High-Efficiency (HE) Series of cryogenic freezers. The HE 800 C combines ergonomic features and consistent performance in a compact size to meet the evolving needs of fertility clinics, biorepositories and clinical laboratories.
Table of Contents
Exclusive indicates content/data unique to MarketsandMarkets and not available with any competitors.
Methodology
This study involved four major activities to estimate the current size of the biobanking market. Exhaustive secondary research was conducted to gather information on the market, its peer markets, and its parent market. These findings, assumptions, and sizing were then validated with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the total market size. Following this, data triangulation was used to estimate the market size of segments and subsegments.
Secondary Research
Secondary research was primarily used to identify and gather information for the extensive, technical, market-oriented, and commercial study. Secondary sources for this study included publications from government sources, such as the European, Middle Eastern & African Society for Biopreservation and Biobanking (ESBB), Biobanking and BioMolecular Resources Research Infrastructure - European Research Infrastructure Consortium (BBMRI-ERIC), International Society for Biological and Environmental Repositories (ISBER), National Institutes of Health (NIH), and the US Food and Drug Administration (US FDA), as well as ScienceDirect and several others. Secondary sources also included corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements); business magazines and research journals; press releases; and trade, business, and professional associations. These sources were used to obtain key information on major players, global product revenues, market classification, and segmentation by industry trends, regional/country-level markets, market developments, and technology perspectives. Secondary data were collected and analyzed to determine the overall size of the global Biobanking market, and the findings were validated through primary research.
Primary Research
In-depth interviews were conducted with primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among others, to obtain and verify critical qualitative and quantitative information and to assess market prospects. Primary sources from both the supply and demand sides of the market were interviewed to gather qualitative and quantitative data. The following is a breakdown of the primary respondents:
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The global size of the biobanking market was estimated using multiple approaches. A detailed market estimation approach was used to estimate and validate the market value and other dependent submarkets. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:
Biobanking Market : Top-Down and Bottom-Up Approach
Data Triangulation
After estimating the overall market size through the market size estimation process, the total market was divided into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, the data triangulation procedure was employed; it involved analyzing various factors and trends from both the demand and supply sides.
Market Definition
Biobanking involves collecting, processing, storing, and managing biological samples—such as blood, tissues, stem cells, nucleic acids, and other human-derived materials—for research, diagnostic, and therapeutic applications. The market includes equipment, consumables, software, and services used by CROs, biobanks, pharmaceutical and biotechnology companies, and academic and research institutions. These entities manage diverse sample types, including blood products, human tissues, stem cells and cell lines, nucleic acids, biological fluids, and human waste products, using manual or automated systems depending on technological adoption. The market is also segmented by ownership models, including academic and research institutions, national and regional agencies, private organizations, and other entities.
Key Stakeholders
- Academic & Research Institutes
- Biobanks
- Contract Research Organizations (CROs)
- Market Research and Consulting Firms
- Pharmaceutical and Biotechnology Companies
- Regulatory Agencies
- Venture Capitalists
- Forensics Labs
- Government organizations
- Private research firms
- Hospitals and Diagnostic Laboratories
Report Objectives
- To define, describe, and forecast the biobanking market by offering, equipment-operation type, service-ownership, product-sample type, application, product-end user, service-end user, and region
- To provide detailed information regarding the major factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
- To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall biobanking market
- To analyze opportunities for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments with respect to six regions: North America (US and Canada), Europe (Germany, France, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), Latin America (Brazil, Mexico, Argentina, and the Rest of Latin America), the Middle East [GCC Countries (Saudi Arabia (KSA), United Arab Emirates (UAE), and the Rest of GCC Countries) and the Rest of Middle East], and Africa
- To profile the key players and analyze their market share and core competencies
- To analyze competitive developments, such as product launches, partnerships, agreements, collaborations, and expansions
- To benchmark players within the market using the proprietary “Company Evaluation Matrix” framework, which analyzes market players on various parameters within the broad categories of business and product excellence strategy
Available customizations:
With the given market data, MarketsandMarkets offers customization as per the company’s specific needs. The following options are available for the report:
Geographical Analysis
- Further breakdown of Rest of Europe biobanking market, by country
- Further breakdown of Rest of Asia Pacific biobanking market, by country
Comapany Information
- Detailed analysis and profiling of additional market players (up to five)
Segment Analysis
- Cross-segment analysis
Frequently Asked Questions (FAQ)
Who are the key players in the biobanking market?
Thermo Fisher Scientific Inc. (US), PHC Holdings Corporation (Japan), Becton, Dickinson and Company (BD) (US), Qiagen (Germany), Merck KGaA (Germany), Labcorp (US), Eurofins Scientific (Luxembourg), Cryoport (US)
Which product segment dominates the biobanking offerings market?
The products segment dominates the market due to its essential role in sample storage, processing, and long-term preservation, ensuring sample integrity for future research.
Which sample type segment is expected to contribute the largest share?
The blood products segment holds the largest share, owing to its versatility and status as the gold-standard for multi-omic analyses including biomarker screening, proteogenomics, and metabolomics.
Which biobanking services end-user segment accounted for the largest share of the market?
Pharmaceutical & biotechnology companies and CROs held the largest share in 2024, driven by growing R&D in regenerative medicine, investments in advanced therapies, and personalized medicine efforts.
What is the market size for the biobanking market?
The biobanking market is expected to grow at a CAGR of 9.1% from 2025 to 2030, increasing from USD 7.65 billion in 2025 to USD 11.82 billion by 2030.
Personalize This Research
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
Let Us Help You
- What are the Known and Unknown Adjacencies Impacting the Biobanking Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
Custom Market Research Services
We Will Customise The Research For You, In Case The Report Listed Above Does Not Meet With Your Requirements
Get 10% Free CustomisationTESTIMONIALS
JAYANT RAJPUROHIT
Director of Market Insights, Data and Analytics
SFI Health,
Leading Pharmaceutical Companywww.sfihealth.com/
We at SFI Health approached MarketsandMarkets for an Opportunity Assessment on "Incidence and Prevalence of Focus Indications" as we wanted to know the most attractive HCPs like Physician, Functional MD, Naturopath and Pharmacist. The project was critical for us to ensure our focus on the right target which would enable sustainable growth and profitability for SFI Health. The business insights provided exceeded our expectations and we were extremely impressed. The team at MarketsandMarkets is highly professional and detail oriented and very well understood our business needs. MarketsandMarkets offers a unique combination of expertise and dedicated engagement model. We identified 2 new products to be launched in coming months, based on the research findings provided by MarketsandMarkets. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
BEATRIZ DE LA CALLE
Head of Commercial Analytics
Qualicaps,
Leading Pharmaceutical Companywww.qualicaps.com/
We partnered with MarketsandMarkets for an assessment study on hard empty capsules. The team was extremely professional in understanding our business requirements and we received timely responses to all our queries. The market intelligence and the recommendations has met our business requirements. We were extremely impressed to see the final study results; it really exceeded our expectations. The market intelligence offered by MarketsandMarkets, and clarity on next steps will help us achieve our business objective for the Year 2021. We are happy with the services and would strongly recommend MarketsandMarkets to my peers in the industry.
Bob Williams,
Senior Director Business Development & Innovation
Bracco Diagnostics Inc.,
Italian Multinational in life sciences sector and a World Leader in imaging diagnosticsimaging.bracco.com/us-en
We were pleased with targeted insights that MarketsandMarkets identified from a custom study on the 'Radiation Dose Management Solutions Market'. Your team identified and characterized the market participants as well as underlying trends accurately. This study was useful to Bracco in formulating business strategies for our dose monitoring product lines and we thank MarketsandMarkets for the job well done.
Cody Coonradt,
Market Development and Strategy Manager
3M Health Information Systems,
Leader in Health care Coding, Payment & Analytics Solutions.www.3m.com/3M/en_US/health-information-systems-us
The value for our organization comes from three things: depth of research, specificity of segments and being easy to work with. As important as the first two are, the third can't be underestimated. MarketsandMarkets, maybe more than any other research vendor, wants to know what is top of mind for our team and what big questions we are grappling to answer.
Their customer first approach and high value engagement model, have given us great analysis and excellent value for money
- Canada Biobanking Market
- US Biobanking Market
- Germany Biobanking Market
- UK Biobanking Market
- France Biobanking Market
- Italy Biobanking Market
- Spain Biobanking Market
- China Biobanking Market
- Japan Biobanking Market
- India Biobanking Market
- Australia Biobanking Market
- South Korea Biobanking Market
- Brazil Biobanking Market
- Mexico Biobanking Market
- UAE Biobanking Market
- Rest Of Europe Biobanking Market
- Rest Of Asia Pacific Biobanking Market
- Rest Of Latin America Biobanking Market
- Ksa Biobanking Market
- Rest Of GCC Countries Biobanking Market
Growth opportunities and latent adjacency in Biobanking Market